Human Epidermal Growth Factor Receptor 2-positive Primary Adenocarcinoma in the Cervical Oesophagus: A Case Report

In Vivo. 2021 Jul-Aug;35(4):2297-2303. doi: 10.21873/invivo.12503.

Abstract

Background/aim: Cervical oesophageal adenocarcinoma (COA) is extremely rare. We present a case of human epidermal growth factor receptor 2 (HER2)-positive COA that showed repeated recurrences despite multidisciplinary treatments.

Case report: A 49-year-old male was diagnosed with clinical stage IVA COA that originated from ectopic gastric mucosa. He initially underwent definitive chemoradiotherapy (CRT) (60.0 Gy/30 fractions, 5-fluorouracil, and cisplatin). Two months after CRT, the right supraclavicular lymph node (LN) reenlarged and salvage lymphadenectomy was performed. Immunohistochemical staining revealed a HER2-positive adenocarcinoma. Four months after lymphadenectomy, multiple metastases in the mediastinal LNs and lungs were detected, and S-1, oxaliplatin and trastuzumab were administered. Four months after chemotherapy, the patient presented with new liver metastasis. Further metastasis was prevented by Nivolumab treatment for four months.

Conclusion: HER2-positive COA may be more aggressive and may require further intensive treatments. This literature review may be helpful in determining treatment strategies for COA.

Keywords: HER2.; Oesophageal adenocarcinoma; cervical oesophagus.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adenocarcinoma* / diagnosis
  • Adenocarcinoma* / drug therapy
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cisplatin / therapeutic use
  • Esophagus
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Receptor, ErbB-2 / genetics
  • Stomach Neoplasms* / drug therapy

Substances

  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Cisplatin